Figure 2: In vitro, the platinum-resistant ovarian cancer A2780/CP70 cells treated with cisplatin showed a 6-fold increase in ERCC1 mRNA level (Figure 2 left panel). This increased mRNA is caused by increased transcription (Figure 2 middle panel) and by prolonged mRNA half-life (Figure 2 right panel). The ERCC1 mRNA half-life is increased or prolonged 8 hours in the cisplatintreated cells compared to untreated control cells [34].